At 4baseCare, we are focusing on disrupting the $47 Billion (2026) Precision Oncology market by leveraging on patients clinical and genetics data. Based on the insights generated, we help Pharma companies, Research Institutes and Healthcare organizations to come up with better strategies (Novel genetic biomarkers, preclinical drug testing models and novel therapeutic targets) for precision and personalized cancer treatment which would lead to improved clinical outcomes.
Momentum is derived from funding recency, velocity, round count and scale.
We Harness Genomic Diversity and AI to Personalize Cancer Care for Every Patient, Everywhere.
Other business activities
Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.